Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has gained exclusive rights to use ImmunoGen's Tumor-Activated Prodrug technology with therapeutic antibodies to an undisclosed target.
Subscribe to our email newsletter
The new license is in addition to an existing agreement between the companies that grants Genentech exclusive rights to use ImmunoGen’s technology with therapeutic antibodies to HER2.
ImmunoGen’s Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. ImmunoGen uses TAP technology to develop its own products, funding programs by selectively out licensing its technology to other companies for use with their proprietary antibodies.
This latest agreement stems from a 2000 agreement between the companies that grants Genentech certain rights to test ImmunoGen’s TAP technology with Genentech’s therapeutic antibodies to specific targets. Under the agreement, Genentech must take a license for each target in order to use ImmunoGen’s technology to develop products with therapeutic antibodies to that target.